Advanced search
Publication Cover
Upsala Journal of Medical Sciences Volume 125, 2020 - Issue 4
Journal homepage
3,098
Views
6
CrossRef citations to date
0
Altmetric
Case Report

Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma

Bengt Tholandera Department of Oncology, Uppsala University Hospital, Uppsala, Sweden;b Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, SwedenCorrespondence[email protected]
,
Anthoula Koliadia Department of Oncology, Uppsala University Hospital, Uppsala, Sweden;b Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden
,
Johan Botlingb Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden
,
Hanna Dahlstranda Department of Oncology, Uppsala University Hospital, Uppsala, Sweden;b Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden
,
Anne Von Heidemana Department of Oncology, Uppsala University Hospital, Uppsala, Sweden;b Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden
,
Håkan Ahlströmc Department of Surgical Sciences, Uppsala Sweden, Division of Radiology, Uppsala University Hospital, Uppsala, Sweden
,
Kjell Öbergd Department of Oncologic Endocrinology, Uppsala University Hospital, Uppsala, Sweden;e Department of Medical Sciences, Uppsala University, Uppsala, Sweden
&
Gustav J. Ullenhaga Department of Oncology, Uppsala University Hospital, Uppsala, Sweden;b Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden
 show all
Pages 325-329 | Received 10 Aug 2020, Accepted 16 Sep 2020, Published online: 10 Oct 2020

Figures & data

Figure 1. Serum levels of CA-125 during course of treatment with combination of BRAF and MEK inhibitors in a patient with low-grade serous ovarian cancer.

Figure 1. Serum levels of CA-125 during course of treatment with combination of BRAF and MEK inhibitors in a patient with low-grade serous ovarian cancer.

Figure 2. Baseline and eight months CT scans demonstrating complete response for a patient with low-grade serous ovarian cancer treated with combination of BRAF and MEK inhibitors. (A) Lung metastases. (B, C) Lymph node metastases at left pelvic wall. (D) Lymph node metastases in left groin.

Figure 2. Baseline and eight months CT scans demonstrating complete response for a patient with low-grade serous ovarian cancer treated with combination of BRAF and MEK inhibitors. (A) Lung metastases. (B, C) Lymph node metastases at left pelvic wall. (D) Lymph node metastases in left groin.
 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.